about
Hypoxia in head and neck cancer in theory and practice: a PET-based imaging approachPET-specific parameters and radiotracers in theoretical tumour modelling.Computational and mathematical modeling of tumor kinetics and response to radiation and chemotherapy.Quo vadis radiotherapy? Technological advances and the rising problems in cancer managementIn silico modelling of a cancer stem cell-targeting agent and its effects on tumour control during radiotherapy.Tirapazamine: from bench to clinical trials.The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments.A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment.Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain.The role of PET imaging in overcoming radiobiological challenges in the treatment of advanced head and neck cancer.Risk of second primary cancer after breast cancer treatment.The effect of targeted therapy on recruited cancer stem cells in a head and neck carcinoma model.PET-based quantification of statistical properties of hypoxic tumor subvolumes in head and neck cancer.Quality indicators and technique for analyzing permanent I-125 prostate seed implants: Seven years postimplant dosimetry evaluation.Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence.Modelling of tumour repopulation after chemotherapy.Radiobiological modeling of interplay between accelerated repopulation and altered fractionation schedules in head and neck cancer.Predictive models of tumour response to treatment using functional imaging techniques.Assessment of I-125 seed implant accuracy when using the live-planning technique for low dose rate prostate brachytherapy.Evaluation of physician eye lens doses during permanent seed implant brachytherapy for prostate cancer.The use of enriched 6Li and 7Li Lif:Mg,Cu,P glass-rod thermoluminescent dosemeters for linear accelerator out-of-field radiation dose measurements.Comparison of 3 different postimplant dosimetry methods following permanent 125I prostate seed brachytherapy.Out-of-field neutron and leakage photon exposures and the associated risk of second cancers in high-energy photon radiotherapy: current status.Tumour resistance to cisplatin: a modelling approach.Treatment technique evolution and dosimetry trends over seven years of low dose rate prostate brachytherapy at an Australian institution.Influence of stem-cell cycle time on accelerated re-population during radiotherapy in head and neck cancer.Risk estimation of second primary cancers after breast radiotherapy.Efficient Monte Carlo modelling of individual tumour cell propagation for hypoxic head and neck cancer.The first Rs of radiotherapy: or standing on the shoulders of giants.Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio.Peripheral photon and neutron doses from prostate cancer external beam irradiation.Stochastic modelling of the role of cisplatin in altered fractionation schedules for head and neck cancer.Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation TherapyThe Promise of Novel Biomarkers for Head and Neck Cancer from an Imaging PerspectiveAssessment of normal tissue complications following prostate cancer irradiation: Comparison of radiation treatment modalities using NTCP modelsScheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approachPhotons – Radiobiological issues related to the risk of second malignanciesTumour repopulation and the role of abortive division in squamous cell carcinomas during chemotherapyModelling of post-irradiation accelerated repopulation in squamous cell carcinomas
P50
Q34151551-CF006CB8-2A4C-4140-BA73-E02DD4079C47Q35151586-81DB1389-6CD1-4E8F-BB49-0A5065333384Q36516141-5886D671-5D48-449F-8485-D01481680AEAQ36933276-08C6236D-B715-4923-880A-91EF08557F32Q37215705-42955B46-2ED3-4064-9068-9DF104AD2B8BQ37230218-A6E73C12-C95B-406C-9639-D30F1C23ACB2Q37408321-A0550848-CF72-4FD7-92D6-D1A6174A3DE7Q37437083-37B5C700-0DA3-43E4-ADF9-1B565D724FF7Q37566349-8E427CEF-341A-4A82-9DC9-E727CB9F249AQ37759893-B8892E34-4FEB-40BE-A43A-75B034EF948FQ37899606-148BCAFA-D863-42C2-A7D1-959BB1BCF824Q38129094-027317B7-71A1-4B0A-85F1-EC47880B1BDFQ38600594-11467ED8-C9A5-4087-8630-AF71C95CEAE6Q38691362-12F4B913-9ADF-4182-A2EC-D03F16B4C4A0Q38779301-240DDF56-FD22-4E28-99CD-8B3BECB1C25DQ38843468-0F60BADB-69C7-4E12-AB7B-2B460706D309Q39676901-0B31670D-43F9-415F-95A9-5C86AED4905BQ41783178-59BD3A7D-6332-40E1-84D9-F8E141BF8EEBQ42257749-7826E1DF-1D04-409B-8F98-83ED344718ABQ42576691-80B3885D-0D0E-480D-BFD7-2F78D49767CAQ43517407-42CB5FBD-6705-4159-B3B4-82E6FC3CEBD8Q44592818-DB4D05A7-5D43-473F-8E99-A35B2336F293Q45243977-544EC86A-A8E6-4193-B270-D5E5EE5ED12EQ45257822-BFDFC5CF-7392-4F74-A6A8-11F6FEAD8874Q45268931-677DAF7D-B4CD-4436-ABC2-76778C5497ECQ46657256-4E3E6DE3-F90B-4933-A536-5109ABC7DED2Q47405445-B5F46AF7-6F68-4A19-80AB-B409D4FF1549Q48638760-335270D9-A59A-4E82-B721-9200CB47FE20Q51871830-9E5BFD47-645F-41AD-A406-0413874E80C7Q52908273-A59FBEB9-086F-4F42-82FB-1CAAD6D75899Q53197893-EC9CD4B7-D066-4ED9-9AB6-BD8AFE91742BQ53225304-357858B3-8EED-4D75-915F-12984597166FQ53352250-A7E1A04B-C3A5-4485-B14E-90B83F03AE56Q58584561-F7F24290-E4AC-4769-94C5-76C73E1CA5F2Q58703820-19E9C244-22F3-43C7-AD8D-3C137C9993EFQ59198631-E42FA5F1-638F-4D36-93E0-20188D525DAFQ59198648-DD92776F-443A-41CC-AD51-CDC560AA1B26Q60671655-8C907C09-F17A-41EE-A3BB-CDE43CF1FBD8Q60671668-D5351B69-05EB-47B5-A24A-E22BBD9FD06DQ60671759-26C0B336-28D1-4058-8814-CEA3BFCDEA55
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Loredana G. Marcu
@ast
Loredana G. Marcu
@en
Loredana G. Marcu
@es
Loredana G. Marcu
@nl
Loredana G. Marcu
@sl
type
label
Loredana G. Marcu
@ast
Loredana G. Marcu
@en
Loredana G. Marcu
@es
Loredana G. Marcu
@nl
Loredana G. Marcu
@sl
prefLabel
Loredana G. Marcu
@ast
Loredana G. Marcu
@en
Loredana G. Marcu
@es
Loredana G. Marcu
@nl
Loredana G. Marcu
@sl
P106
P1153
7006835272
P21
P2456
P31
P496
0000-0002-6703-979X